On February 19, 2020 United Therapeutics Corporation (Nasdaq: UTHR) reported that it will report its fourth quarter and full year 2019 financial results before the market opens on Wednesday, February 26, 2020 (Press release, United Therapeutics, FEB 19, 2020, View Source [SID1234554531]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

United Therapeutics will host a teleconference on Wednesday, February 26, 2020, at 9:00 a.m. Eastern Time. The teleconference is accessible by dialing (866) 209-9943 in the United States, with international callers dialing +1 (825) 312-2282. A rebroadcast of the teleconference will be available for one week and can be accessed by dialing (800) 585-8367 in the United States, with international callers dialing +1 (416) 621-4642, and using access code: 1598163.

This teleconference is also being webcast and can be accessed via United Therapeutics’ website at View Source

On February 19, 2020 Caris Life Sciences, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, reported that Brian Brille, Vice Chairman of the Company, will present at the Cowen and Company 40th Annual Health Care Conference on Tuesday, March 3, 2020, at 9:30 a.m. Eastern time (Press release, Caris Life Sciences, FEB 19, 2020, https://www.prnewswire.com/news-releases/caris-life-sciences-to-present-at-cowen-and-company-40th-annual-health-care-conference-301007123.html [SID1234554530]). The conference is being held at the Boston Marriott Copley Place, Boston.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mr. Brille will provide an overview of the business and discuss recent corporate achievements that position Caris to further extend its leadership in the precision medicine market. He also will take questions from the audience.

Investors attending the conference who would like to schedule a one-on-one meeting with Caris executives may do so by contacting their Cowen representative.

On February 19, 2020 Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) reported that it will host a live webcast on Wednesday, February 26th at 11:30 a.m. Eastern Time to discuss its 2019 financial results and report on pipeline and business progress (Press release, Ionis Pharmaceuticals, FEB 19, 2020, View Source [SID1234554529]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Click here to access the audio webcast and slides. A webcast replay will remain posted on Ionis’ website for a limited time.

On February 19, 2020 Ardelyx, Inc. (NASDAQ: ARDX) reported that Mike Raab, president and chief executive officer of Ardelyx, will present at the 9th Annual SVB Leerink Global Healthcare Conference at 3:30 p.m. ET on Wednesday, Feb. 26, 2020 in New York City (Press release, Ardelyx, FEB 19, 2020, View Source [SID1234554528]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the live webcast of Ardelyx’s presentation please visit the Events & Presentations page within the Investor section of the Ardelyx website at ir.ardelyx.com. A replay of the webcast will be available on the Ardelyx website for 60 days following the conference.

On February 19, 2020 Bolt Biotherapeutics, a private biotechnology company focused on using its Immune-Stimulating Antibody Conjugate (ISAC) platform technology to harness the power of the immune system to treat cancer, reported that Randall C. Schatzman, PhD., Chief Executive Officer, will present at the SVB Leerink 9th Annual Global Healthcare Conference on Tuesday, February 25, 2020 at 1:30 p.m. ET in New York, NY (Press release, Bolt Biotherapeutics, FEB 19, 2020, View Source [SID1234554527]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!